Company news

Trevi Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026

November 2, 2026

Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference

October 27, 2026

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

October 13, 2026

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

August 26, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026

Trevi Therapeutics Announces Upcoming June and July Event Schedule

June 17, 2026

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

April 29, 2026

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

April 28, 2026

Trevi Therapeutics to Participate in Upcoming May Events

April 23, 2026

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

April 20, 2026

Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

April 16, 2026

Trevi Therapeutics to Participate in Upcoming Events

March 31, 2026

Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

March 16, 2026

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

March 9, 2026

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

March 8, 2026

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

January 22, 2026

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

January 8, 2026

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

December 3, 2025

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 12, 2025

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

November 5, 2025

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

November 3, 2025

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

October 7, 2025

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

September 17, 2025

Trevi Therapeutics to Participate in Upcoming September Conferences

August 27, 2025

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

July 30, 2025

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

June 30, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 4, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 2, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 1, 2025

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 31, 2025

Trevi Therapeutics to Participate in Upcoming June Conferences

May 28, 2025

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 19, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

April 30, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

April 2, 2025

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

March 17, 2025

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

March 10, 2025

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

March 9, 2025

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

March 8, 2025

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

February 26, 2025

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

February 24, 2025

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

January 29, 2025

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

January 7, 2025

Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.